As we demonstrated that the use of whole dead/dying glioma GL261 cells as prophylactic vaccines provide effective protection against challenges with viable glioma cells in mice, the final part of our study aimed to validate the immunogenic potential of DC vaccines loaded with the lysates of glioma GL261 cells that underwent ICD after pz I-PDT or pz III-PDT treatment. This evidence concerns the gene PROZ and central nervous system cancer.